Retispec announces collaboration and investment from Topcon Healthcare to help bring eye-based AI diagnostic tool to market

RetiSpec, Inc., an innovator in AI-powered eye diagnostics for brain health, and Topcon Healthcare, Inc. a leading provider of medical devices and software solutions recently announced that Topcon has invested in RetiSpec and the two companies are collaborating to bring the RetiSpec technology to market. The collaboration will bring neurology and eye care closer together.

The collaboration between Topcon Healthcare, Inc. and RetiSpec will accelerate the commercialization and scale of RetiSpec's first brain health indication in Alzheimer's disease. It will also help expedite development of additional AI-powered diagnostic solutions from the eye for early detection and monitoring of neurodegenerative diseases and side effects of the new therapies for Alzheimer's disease.

Retispec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.